Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial

Charles Laudadio, Anders A F Sima, V. Bril, R. Clements, D. Bell, A. Charles, A. Mehta, N. Pillay, D. Porte, P. Raskin, H. Schaumburg, J. Sosenko, A. Vinik, C. Laudadio, R. D. Aitchison, Joseph C. Arezzo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Recent clinical drug trials designed to test the effect on established mild diabetic neuropathy have in general been disappointing. These findings may in part be due to a failure of tested drugs to reverse neuropathy (they may merely halt its progression) and to insufficient durations of the trials. To aid the design of future studies, we examined the progression rates of quantitative sensory tests, autonomic functions, and sensory and motor nerve electrophysiology in 182 patients designed to placebo treatment in an 18-month multicenter ARI-trial. Clinically meaningful deteriorations were demonstrated in the vibratory perception threshold in the toe and the Valsalva ratio. The greatest deterioration rate in electrophysiologic measures was found in peroneal F-wave latency and in sensory nerve conduction velocities in the upper limb, but none of these reached the threshold of clinically meaningful change. Assuming that drug efficacy will be based on the deterioration rates in placebo patients alone, the present data suggest a minimum of 250 patients treated for at least 2 years to achieve convincing efficacy.

Original languageEnglish (US)
Pages (from-to)121-127
Number of pages7
JournalJournal of Diabetes and its Complications
Volume12
Issue number3
DOIs
StatePublished - May 1998
Externally publishedYes

Fingerprint

Diabetic Neuropathies
Placebos
Clinical Trials
Pharmaceutical Preparations
Electrophysiology
Neural Conduction
Toes
Upper Extremity
Multicenter Studies
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. / Laudadio, Charles; Sima, Anders A F; Bril, V.; Clements, R.; Bell, D.; Charles, A.; Mehta, A.; Pillay, N.; Porte, D.; Raskin, P.; Schaumburg, H.; Sosenko, J.; Vinik, A.; Laudadio, C.; Aitchison, R. D.; Arezzo, Joseph C.

In: Journal of Diabetes and its Complications, Vol. 12, No. 3, 05.1998, p. 121-127.

Research output: Contribution to journalArticle

Laudadio, C, Sima, AAF, Bril, V, Clements, R, Bell, D, Charles, A, Mehta, A, Pillay, N, Porte, D, Raskin, P, Schaumburg, H, Sosenko, J, Vinik, A, Laudadio, C, Aitchison, RD & Arezzo, JC 1998, 'Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial', Journal of Diabetes and its Complications, vol. 12, no. 3, pp. 121-127. https://doi.org/10.1016/S1056-8727(97)00074-3
Laudadio, Charles ; Sima, Anders A F ; Bril, V. ; Clements, R. ; Bell, D. ; Charles, A. ; Mehta, A. ; Pillay, N. ; Porte, D. ; Raskin, P. ; Schaumburg, H. ; Sosenko, J. ; Vinik, A. ; Laudadio, C. ; Aitchison, R. D. ; Arezzo, Joseph C. / Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. In: Journal of Diabetes and its Complications. 1998 ; Vol. 12, No. 3. pp. 121-127.
@article{4f92cc7e41ef4ea4b0c5c6ba0a7dcfac,
title = "Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial",
abstract = "Recent clinical drug trials designed to test the effect on established mild diabetic neuropathy have in general been disappointing. These findings may in part be due to a failure of tested drugs to reverse neuropathy (they may merely halt its progression) and to insufficient durations of the trials. To aid the design of future studies, we examined the progression rates of quantitative sensory tests, autonomic functions, and sensory and motor nerve electrophysiology in 182 patients designed to placebo treatment in an 18-month multicenter ARI-trial. Clinically meaningful deteriorations were demonstrated in the vibratory perception threshold in the toe and the Valsalva ratio. The greatest deterioration rate in electrophysiologic measures was found in peroneal F-wave latency and in sensory nerve conduction velocities in the upper limb, but none of these reached the threshold of clinically meaningful change. Assuming that drug efficacy will be based on the deterioration rates in placebo patients alone, the present data suggest a minimum of 250 patients treated for at least 2 years to achieve convincing efficacy.",
author = "Charles Laudadio and Sima, {Anders A F} and V. Bril and R. Clements and D. Bell and A. Charles and A. Mehta and N. Pillay and D. Porte and P. Raskin and H. Schaumburg and J. Sosenko and A. Vinik and C. Laudadio and Aitchison, {R. D.} and Arezzo, {Joseph C.}",
year = "1998",
month = "5",
doi = "10.1016/S1056-8727(97)00074-3",
language = "English (US)",
volume = "12",
pages = "121--127",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial

AU - Laudadio, Charles

AU - Sima, Anders A F

AU - Bril, V.

AU - Clements, R.

AU - Bell, D.

AU - Charles, A.

AU - Mehta, A.

AU - Pillay, N.

AU - Porte, D.

AU - Raskin, P.

AU - Schaumburg, H.

AU - Sosenko, J.

AU - Vinik, A.

AU - Laudadio, C.

AU - Aitchison, R. D.

AU - Arezzo, Joseph C.

PY - 1998/5

Y1 - 1998/5

N2 - Recent clinical drug trials designed to test the effect on established mild diabetic neuropathy have in general been disappointing. These findings may in part be due to a failure of tested drugs to reverse neuropathy (they may merely halt its progression) and to insufficient durations of the trials. To aid the design of future studies, we examined the progression rates of quantitative sensory tests, autonomic functions, and sensory and motor nerve electrophysiology in 182 patients designed to placebo treatment in an 18-month multicenter ARI-trial. Clinically meaningful deteriorations were demonstrated in the vibratory perception threshold in the toe and the Valsalva ratio. The greatest deterioration rate in electrophysiologic measures was found in peroneal F-wave latency and in sensory nerve conduction velocities in the upper limb, but none of these reached the threshold of clinically meaningful change. Assuming that drug efficacy will be based on the deterioration rates in placebo patients alone, the present data suggest a minimum of 250 patients treated for at least 2 years to achieve convincing efficacy.

AB - Recent clinical drug trials designed to test the effect on established mild diabetic neuropathy have in general been disappointing. These findings may in part be due to a failure of tested drugs to reverse neuropathy (they may merely halt its progression) and to insufficient durations of the trials. To aid the design of future studies, we examined the progression rates of quantitative sensory tests, autonomic functions, and sensory and motor nerve electrophysiology in 182 patients designed to placebo treatment in an 18-month multicenter ARI-trial. Clinically meaningful deteriorations were demonstrated in the vibratory perception threshold in the toe and the Valsalva ratio. The greatest deterioration rate in electrophysiologic measures was found in peroneal F-wave latency and in sensory nerve conduction velocities in the upper limb, but none of these reached the threshold of clinically meaningful change. Assuming that drug efficacy will be based on the deterioration rates in placebo patients alone, the present data suggest a minimum of 250 patients treated for at least 2 years to achieve convincing efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0031747355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031747355&partnerID=8YFLogxK

U2 - 10.1016/S1056-8727(97)00074-3

DO - 10.1016/S1056-8727(97)00074-3

M3 - Article

C2 - 9618066

AN - SCOPUS:0031747355

VL - 12

SP - 121

EP - 127

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 3

ER -